USD
+$0.00
(+0.00%
)At Close (As of Sep 18, 2025)
$41.51M
Market Cap
-
P/E Ratio
-0.4
EPS
$1.64
52 Week High
$0.66
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $3.7M |
Total Revenue | $3.7M |
Cost Of Revenue | $0 |
Costof Goods And Services Sold | $0 |
Operating Income | -$37M |
Selling General And Administrative | $14M |
Research And Development | $26M |
Operating Expenses | $41M |
Investment Income Net | - |
Net Interest Income | $1.7M |
Interest Income | $4.3M |
Interest Expense | $2.6M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.7M |
Income Before Tax | -$21M |
Income Tax Expense | $151K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$21M |
Comprehensive Income Net Of Tax | - |
Ebit | -$20M |
Ebitda | -$19M |
Net Income | -$21M |
Field | Value (USD) |
---|---|
Total Assets | $91M |
Total Current Assets | $72M |
Cash And Cash Equivalents At Carrying Value | $16M |
Cash And Short Term Investments | $16M |
Inventory | - |
Current Net Receivables | $10M |
Total Non Current Assets | $18M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $16M |
Short Term Investments | $43M |
Other Current Assets | $2.6M |
Other Non Current Assets | - |
Total Liabilities | $36M |
Total Current Liabilities | $24M |
Current Accounts Payable | $4.6M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $15M |
Total Non Current Liabilities | $11M |
Capital Lease Obligations | $2.6M |
Long Term Debt | - |
Current Long Term Debt | $14M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $16M |
Other Current Liabilities | $3.4M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $55M |
Treasury Stock | - |
Retained Earnings | -$377M |
Common Stock | $41K |
Common Stock Shares Outstanding | $49M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$24M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.7M |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | $0 |
Profit Loss | - |
Cashflow From Investment | $6.2M |
Cashflow From Financing | -$139K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$21M |
Field | Value (USD) |
---|---|
Gross Profit | $3.7M |
Total Revenue | $3.7M |
Cost Of Revenue | $0 |
Costof Goods And Services Sold | $0 |
Operating Income | -$37M |
Selling General And Administrative | $14M |
Research And Development | $26M |
Operating Expenses | $41M |
Investment Income Net | - |
Net Interest Income | $1.7M |
Interest Income | $4.3M |
Interest Expense | $2.6M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.7M |
Income Before Tax | -$21M |
Income Tax Expense | $151K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$21M |
Comprehensive Income Net Of Tax | - |
Ebit | -$20M |
Ebitda | -$19M |
Net Income | -$21M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medical needs in infectious diseases, Scynexis is well-positioned to enhance its market presence within the evolving landscape of antifungal treatments.